4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Overview | Financials
Company Name | 4D Molecular Therapeutics, Inc. |
Symbol | FDMT |
Currency | USD |
Price | 8.095 |
Market Cap | 420,693,912 |
Dividend Yield | 0% |
52-week-range | 7.9 - 36.25 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. David H. Kirn M.D. |
Website | https://www.4dmoleculartherapeutics.com |
An error occurred while fetching data.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD